Midatech Pharma PLC (LON:MTPH)‘s stock had its “buy” rating reaffirmed by research analysts at Panmure Gordon in a report issued on Wednesday. They currently have a GBX 380 ($4.96) price objective on the stock. Panmure Gordon’s target price would indicate a potential upside of 157.63% from the stock’s previous close.

Separately, N+1 Singer dropped their price objective on Midatech Pharma PLC from GBX 385 ($5.03) to GBX 300 ($3.92) and set a “buy” rating for the company in a research report on Wednesday, June 1st.

Shares of Midatech Pharma PLC (LON:MTPH) opened at 145.7502 on Wednesday. The stock’s market capitalization is GBX 48.89 million. Midatech Pharma PLC has a 1-year low of GBX 100.51 and a 1-year high of GBX 285.00. The company’s 50 day moving average is GBX 141.39 and its 200-day moving average is GBX 143.63.

This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at http://www.americanbankingnews.com/2016/09/21/midatech-pharma-plc-mtph-rating-reiterated-by-panmure-gordon-2.html

Midatech Pharma PLC Company Profile

Midatech Pharma PLC is an early-stage biopharmaceutical company that focuses on commercializing and developing products in oncology and other therapeutic areas. The Company’s segments include Pipeline Research and Development, and Commercial. The Pipeline Research and Development segment seeks to develop products using the nanomedicine and sustained release technology platforms.

Receive News & Ratings for Midatech Pharma PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Midatech Pharma PLC and related companies with MarketBeat.com's FREE daily email newsletter.